Evicenter
Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in Herpes zoster prevention
Manufacturer
GlaxoSmithKline Biologicals; GlaxoSmithKline
Prescribing information
Shingrix (opens in a new tab)
Questions
47
Last updated

All questions

Safety: Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in herpes zoster prevention

10 questions · 4 sources

Side effects

Shingrix side effects: which are most common in adults 50 and older?

Applies to Prevention of herpes zoster (shingles) in adults aged 50 years and older

How common are Shingrix side effects vs placebo by age in adults 50 and older?

Applies to Prevention of herpes zoster (shingles) in adults aged 50 years and older

“Solicited local and general adverse reactions within 7 days of vaccination (data from ZOE-50 & pooled analysis from ZOE-50 & ZOE-70) Age 50-59 years old 60-69 years old ≥70 years old SHINGRIX % Placebo % SHINGRIX % Placebo % SHINGRIX % Placebo % Local adverse reactions n=1315 n=1312 n=1311 n=1305 n=2258 n=2263 Pain 88 14 83 11 69 9 Pain, Grade 3* 10 1 7 1 4 0.2 Redness 39 1 38 2 38 1 Redness, >100 mm 3 0 3 0 3 0 Swelling 31 1 27 1 23 1 Swelling, >100 mm 1 0 1 0 1 0 General adverse reactions n=1315 n=1312 n=1309 n=1305 n=2252 n=2264 Myalgia 57 15 49 11 35 10 Myalgia, Grade 3† 9 1 5 1 3 0.4 Fatigue 57 20 46 17 37 14 Fatigue, Grade 3† 9 2 5 1 4 1 Headache 51 22 40 16 29 12 Headache, Grade 3† 6 2 4 0.2 2 0.4 Shivering 36 7 30 6 20 5 Shivering, Grade 3† 7 0.2 5 0.3 2 0.3 Fever‡ 28 3 24 3 14 3 Fever, Grade 3§ 0.4 0.2 1 0.2 0.1 0.1 GI‖ 24 11 17 9 14 8 GI, Grade 3† 2 1 1 1 1 0.4 In ZOE-50 and ZOE-70, data on solicited local and general adverse reactions were collected using standardized diary cards for 7 days following each vaccine dose or placebo (ie, day of vaccination and the next 6 days) in a subset of subjects (n=4886 receiving SHINGRIX, n=4881 receiving placebo with at least 1 documented dose). Data for subjects 50-59 years and 60-69 years are from ZOE-50 and data for subjects 70 years and older are based on pooled data from ZOE-50 and ZOE-70. * Grade 3 pain defined as significant pain at rest; prevents normal everyday activities. † Grade 3 myalgia, fatigue, headache, shivering, and GI: defined as preventing normal activity. ‡ Fever defined as ≥37.5°C/99.5°F for oral, axillary, or tympanic route, or ≥38°C/100.4°F for rectal route. § Grade 3 fever defined as >39.0°C/102.2°F. ‖ Included nausea, vomiting, diarrhea, and/or abdominal pain. n=number of subjects with at least 1 documented dose of either SHINGRIX or placebo included in the total vaccinated cohort for safety.” (opens the source at this quote in a new tab)

Are Shingrix side effects worse after the second dose in adults 50 and older?

Applies to Prevention of herpes zoster (shingles) in adults aged 50 years and older

What other Shingrix side effects occurred within 30 days in adults 50 and older?

Applies to Prevention of herpes zoster (shingles) in adults aged 50 years and older

Shingrix serious adverse events vs placebo: how common in adults 50 and older?

Applies to Prevention of herpes zoster (shingles) in adults aged 50 years and older

What are Shingrix side effects in immunocompromised adults 18 and older?

Applies to Prevention of herpes zoster (shingles) in adults aged 18 years and older who are or will be at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy

Note: The percentages are from the auHSCT study (NCT01610414), the largest of the 6 studies in immunocompromised adults. The first passage is from the Patient Counseling page and the others from the Safety Profile page of the immunocompromised section of the Shingrix HCP site.

Shingrix serious adverse events: how common in immunocompromised adults 18 and older?

Applies to Prevention of herpes zoster (shingles) in adults aged 18 years and older who are or will be at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy

“were reported in 46% and 44% of subjects who received SHINGRIX or placebo. Adverse events of arthralgia, infective pneumonia, and influenza-like illness occurred in ≥1% of recipients of SHINGRIX and at a rate at least 1.5-fold higher than placebo (1.5% versus 1.0%, 1.5% versus 0.9%, and 1.3% versus 0.6%, respectively). Serious Adverse Events: Across all 6 studies enrolling immunocompromised subjects, SAEs were reported at similar rates in subjects who received SHINGRIX (7%) or placebo (8%) from the first administered dose up to 30 days post-last vaccination. SAEs were reported for 26% of subjects who received SHINGRIX and for 27% of subjects who received placebo from the first administered dose up to 1 year post-last vaccination. SAEs of infective pneumonia were reported for 21 subjects (1.3%) who received SHINGRIX and for 11 subjects (0.7%) who received placebo up to 30 days post-last vaccination. Available information is insufficient to determine a causal relationship to vaccination. Deaths: Across all 6 studies enrolling immunocompromised subjects, from the first administered dose up to 30 days post-last vaccination, deaths were reported for 2 subjects (0.1%) who received SHINGRIX and 7 subjects (0.5%) who received placebo. From the first administered dose up to 1 year post-last vaccination, deaths were reported for 6% of subjects who received SHINGRIX and for 6% of subjects who received placebo. Causes of death among subjects were consistent with those expected in the populations evaluated.” (opens the source at this quote in a new tab)

Safety

Does Shingrix increase immune-mediated diseases vs placebo in adults 50 and older?

Applies to Prevention of herpes zoster (shingles) in adults aged 50 years and older

Did Shingrix affect relapse, graft rejection, or HIV vs placebo in immunocompromised adults?

Applies to Prevention of herpes zoster (shingles) in adults aged 18 years and older who are or will be at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy

Note: The Safety Profile page of the immunocompromised section of the Shingrix HCP site gives the Shingrix denominator of the NCT01610414 study as 992 in its table; the Prescribing Information gives 315 of 922.

Warnings

Does Shingrix increase the risk of Guillain-Barré syndrome (GBS)?

Applies to Medicare beneficiaries aged 65 years or older (postmarketing observational studies of Guillain-Barre syndrome)

“In one study, using Medicare claims data, from October 2017 through February 2020, vaccinations with SHINGRIX among beneficiaries were identified through National Drug Codes, and potential cases of hospitalized GBS among recipients of SHINGRIX were identified through International Classification of Diseases codes. The risk of GBS following vaccination with SHINGRIX was assessed in self-controlled case series analyses using a risk window of 1 to 42 days postvaccination and a control window of 43 to 183 days postvaccination. Medical record review of GBS cases was conducted to estimate the Positive Predictive Value (PPV) of the claims algorithm. PPV-adjusted risk estimates were calculated by imputing GBS status for all claims-identified cases. These analyses included GBS cases in which other vaccinations were administered the same day or within 42 days of SHINGRIX. The primary analysis, which did not distinguish between doses, found an increased risk of GBS during the 42 days following vaccination with SHINGRIX, with an estimated 3 excess cases (95% confidence interval [CI]: 0.6, 5.6) of GBS per million doses administered to adults aged 65 years or older. In secondary analyses, an increased risk of GBS was observed during the 42 days following the first dose of SHINGRIX, with an estimated 6 excess cases (95% CI: 3.4, 9.6) of GBS per million doses administered to adults aged 65 years or older, and no increased risk of GBS was observed following the second dose of SHINGRIX. A separate similarly-designed study also evaluated the association between vaccination with SHINGRIX and GBS among Medicare beneficiaries aged 65 years or older. Using Medicare claims data, from January 2018 through December 2020, vaccinations with SHINGRIX among beneficiaries were identified through National Drug Codes and Current Procedural Terminology codes. Potential cases of hospitalized GBS among recipients of SHINGRIX were identified through International Classification of Diseases codes.” (opens the source at this quote in a new tab)

Note: The Prescribing Information lists this Guillain-Barré syndrome warning (section 5.2) under Recent Major Changes, dated 2/2026.